Cyclerion Therapeutics (CYCN) Stock Jumps 160% Following Korsana Biosciences Merger Announcement

Key Highlights

• Cyclerion Therapeutics (CYCN) skyrocketed more than 160% during pre-market hours following the announcement of a reverse merger with Korsana Biosciences
• The newly formed company will be named Korsana Biosciences and will list on Nasdaq using the ticker symbol “KRSA”
• Existing Cyclerion shareholders will control only 1.5% of the merged entity, while Korsana investors will command 98.5%
• Korsana has raised $380 million in private funding spearheaded by Fairmount and Venrock Healthcare Capital Partners, featuring investments from J.P. Morgan, Janus Henderson, and Sanofi Ventures
• The flagship candidate KRSA-028 is focused on Alzheimer’s disease treatment, with Phase 1 results anticipated in mid-2027 and proof-of-concept findings expected by year-end 2027

On April 1, 2026, Cyclerion Therapeutics disclosed that it has signed a definitive all-stock merger agreement with Korsana Biosciences, a privately-held biotechnology firm. The announcement triggered a surge of more than 160% in CYCN’s pre-market share price.

Cyclerion Therapeutics, Inc., CYCN

This transaction represents an almost complete reverse takeover. Current Cyclerion stockholders will maintain merely 1.5% ownership in the merged organization, while Korsana’s existing shareholders will control the remaining 98.5%.

Following the deal’s completion, Cyclerion will essentially disappear as a standalone publicly-traded company. The merged entity will assume the Korsana Biosciences identity and will be listed on Nasdaq trading under the symbol “KRSA.”

Both companies’ boards of directors have already granted approval for the transaction. The merger is projected to finalize during the third quarter of 2026, subject to shareholder ratification, SEC registration approval, and other customary closing requirements.

Supporting this merger is a significantly oversubscribed private financing round that raised approximately $380 million. Fairmount and Venrock Healthcare Capital Partners led the investment, joined by Janus Henderson (JHG), J.P. Morgan Life Sciences Private Capital, and Sanofi Ventures (SNY).

This substantial capital injection is earmarked to sustain operations until 2029, providing the merged company with sufficient resources to push its primary program through critical clinical development stages.

The Core Asset Driving the Transaction

Korsana’s flagship program, KRSA-028, represents a novel shuttled monoclonal antibody developed to combat Alzheimer’s disease. The therapeutic agent targets amyloid beta utilizing the company’s exclusive Therapeutic Targeting technology, which combines transferrin receptor and Fc engineering to enhance brain penetration.

The treatment is formulated for subcutaneous delivery, potentially offering greater convenience compared to existing intravenous alternatives. Approximately 60 million individuals globally are affected by Alzheimer’s disease.

Initial Phase 1 data from healthy volunteers is projected for mid-2027. Preliminary proof-of-concept results assessing amyloid plaque reduction in Alzheimer’s patients are scheduled for late 2027.

Jonathan Violin, who currently serves as Korsana’s CEO, will assume leadership of the combined organization. Korsana’s existing Board of Directors will transition to the merged company, with Tomas Kiselak from Fairmount taking the chairman position.

Cyclerion’s Path to the Merger

For Cyclerion, this agreement represents the culmination of a strategic alternatives evaluation. The company had been assessing various options after conducting earlier development work on CYC-126, its treatment-resistant depression candidate.

The FDA had recently delivered favorable written commentary regarding Cyclerion’s proposed Phase 2 trial for CYC-126. The company had also established a partnership with Medsteer to develop a closed-loop anesthetic delivery system utilizing EEG-guided technology for that program.

These initiatives will likely be deprioritized as the combined company concentrates on Korsana’s Alzheimer’s-focused pipeline. Wedbush Securities served as financial advisor to Korsana in the transaction; Gemini Valuation Services provided advisory services to Cyclerion.

Before today’s dramatic movement, CYCN had gained approximately 15% during the previous three-month period. The stock had been trading roughly 59% beneath its 52-week peak of $3.79 prior to the merger announcement.